Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Thomas Sarkodie"'
Autor:
Peter W. Szlosarek, Ben Creelan, Thomas Sarkodie, Luke Nolan, Paul Taylor, Olga Olevsky, Federica Grosso, Diego Cortinovis, Meenali Chitnis, Amy Roy, David Gilligan, Hedy Kindler, Dionysis Papadatos-Pastos, Giovanni L. Ceresoli, Aaron Mansfield, Anne Tsao, Ken O’Byrne, Anna K. Nowak, Jeremy Steele, Michael Sheaff, Amanda Johnston, John Bomalaski, Marjorie Zauderer, Dean A. Fennell
Publikováno v:
Cancer Research. 83:CT007-CT007
Background: Arginine deprivation with ADI-PEG20 (pegargiminase) alone or combined with chemotherapy displayed antitumor activity in early phase clinical trials of argininosuccinate synthase 1 (ASS1)-deficient cancers, including pleural mesothelioma (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b667d59b08f57301e511b31f43d6cac
https://doi.org/10.1158/1538-7445.am2023-ct007
https://doi.org/10.1158/1538-7445.am2023-ct007
Autor:
Mohammad Islam, Abby Cyriac, Tarun Durga, Thomas Sarkodie, Gulshad Begum, Joanne Evans, Sreekanth Palvai, Khin Tun
Publikováno v:
Lung Cancer. 178:S55
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::836df64d515db37ed049ec9b633bf634
https://doi.org/10.1016/s0169-5002(23)00554-8
https://doi.org/10.1016/s0169-5002(23)00554-8
Autor:
Thomas Sarkodie, Paul Ross
Publikováno v:
Journal of Medical Case Reports
Journal of Medical Case Reports, Vol 4, Iss 1, p 338 (2010)
Journal of Medical Case Reports, Vol 4, Iss 1, p 338 (2010)
Introduction Sorafenib, an oral multitargeted tyrosine kinase inhibitor, is licensed for the treatment of hepatocellular carcinoma. Rash is one of the most common side effects of its use, generally appearing within days to a few weeks of commencing t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d693f6569fa1126eba8add8aa6f924ba
https://pubmed.ncbi.nlm.nih.gov/20973944
https://pubmed.ncbi.nlm.nih.gov/20973944